Business
Napo Pharmaceuticals to Exhibit at the October 25-28 Annual Association of Nurses in AIDS Care (ANAC) Conference for Mytesi, the Company’s FDA-Approved Prescription Drug
Mytesi® (crofelemer) is indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapyNapo to host
About this update from Jaguar Health, Inc.
[{"type":"text","content":"Mytesi® (crofelemer) is indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapyNapo to host educational dinner for nurses about HIV-related diarrhea and Mytesi during conferenceSAN FRANCISCO, CA / ACCESSWIRE / October 18, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that it will exhibit at the Annual Association of Nurses in AIDS Care (ANAC) Conference, which takes place October 25-28, 2023 at the New Orleans Marriott in New Orleans, Louisiana. Mytesi (crofelemer) is Napo's oral plant-based prescription drug that is FDA-approved and commercially available for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy.The company is also hosting an educational dinner for nurses about HIV-related diarrhea and Mytesi during the conference.The Annual ANAC Conference brings together nearly 500 nurses, nurse educators and other healthcare providers to network and learn more about important topics like pharmaceutical breakthroughs, racial disparities, The Plan to End HIV, and more.About CrofelemerCrofelemer is the only oral FDA-approved prescription drug under botanical guidance. It is plant-based, extracted and purified from the red bark sap of the Croton lechleri tree in the Amazon Rainforest. Jaguar family company Napo Pharmaceuticals has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for Indigenous communities.About the Jaguar Health Family of CompaniesJaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, and bowel incontinence. Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo Pharmaceuticals' crofelemer drug product candidate is the subject of th...